Mortality under plausible interventions on antiretroviral treatment and depression in HIV-infected women: an application of the parametric g-formula
- PMID: 28939001
- PMCID: PMC5714697
- DOI: 10.1016/j.annepidem.2017.08.021
Mortality under plausible interventions on antiretroviral treatment and depression in HIV-infected women: an application of the parametric g-formula
Abstract
Purpose: Among HIV-infected persons, antiretroviral therapy (ART) and depression are strongly associated with mortality. We estimated reductions in 5-year mortality in Women's Interagency HIV Study participants under plausible hypothetical increases in ART initiation and reductions in depression (CES-D score≥16).
Methods: We followed 885 ART-naïve Women's Interagency HIV Study participants for 5 years from their first study visit after April 1998 to death or censoring. We used the parametric extended g-formula to estimate cumulative mortality under the natural course (NC) and alternative exposure distributions.
Results: Baseline prevalence of depression was 52% and 62% initiated ART by 5 years. Compared with mortality under NC (13.2%), immediate ART and elimination of 36% or 67% of depressive episodes were associated with risk differences (RDs) of -5.2% (95% CI: -7.7%, -2.6%) and -5.7 (95% CI: -8.7, -2.7). Compared with immediate ART and NC for depression, additionally eliminating 67% of the depressive episodes was associated with RD = -1.6 (95% CI: -3.9, 0.8). Compared with 5-year mortality under NC for ART and elimination of 67% of depression, also initiating ART immediately was associated with RD = -2.6 (95% CI: -5.0, -0.3).
Conclusions: Increasing ART initiation and reducing depression were associated with moderate reductions in 5-year mortality among HIV-infected women.
Keywords: Antiretroviral therapy; Cohort studies; Depression; HIV; Mortality; Survival analysis.
Copyright © 2017 Elsevier Inc. All rights reserved.
Conflict of interest statement
Figures
References
-
- Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725–33. - PubMed
-
- Nanni MG, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L. Depression in HIV infected patients: a review. Curr Psychiatry Rep. 2015;17(1):530. - PubMed
-
- Tegger MK, Crane HM, Tapia KA, Uldall KK, Holte SE, Kitahata MM. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS. 2008;22(3):233–43. - PubMed
-
- Horberg MA, Silverberg MJ, Hurley LB, Towner WJ, Klein DB, Bersoff-Matcha S, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;47(3):384–90. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 AI103397/AI/NIAID NIH HHS/United States
- U01 AI031834/AI/NIAID NIH HHS/United States
- U01 HL121812/HL/NHLBI NIH HHS/United States
- U01 AI034994/AI/NIAID NIH HHS/United States
- UL1 TR000454/TR/NCATS NIH HHS/United States
- U01 AI103408/AI/NIAID NIH HHS/United States
- U01 HL146194/HL/NHLBI NIH HHS/United States
- KL2 TR001432/TR/NCATS NIH HHS/United States
- U01 AI034989/AI/NIAID NIH HHS/United States
- U01 AI103401/AI/NIAID NIH HHS/United States
- K01 AI125087/AI/NIAID NIH HHS/United States
- U01 AI103390/AI/NIAID NIH HHS/United States
- U01 AI034993/AI/NIAID NIH HHS/United States
- R01 AI100654/AI/NIAID NIH HHS/United States
- UL1 TR000004/TR/NCATS NIH HHS/United States
- P30 AI050410/AI/NIAID NIH HHS/United States
- U01 HD032632/HD/NICHD NIH HHS/United States
- U01 AI042590/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
